NCT05838131

Study of CT071 Injection in RRMM or PPCL

A Clinical Trial to Explore the Safety and Efficacy of CT071 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Detailed description

This trial is a single-arm, open-label, dose-finding, first-in-human clinical trial. The main aim of this study is to preliminarily evaluate the safety and tolerability of CT071 after infusion, and explore the dose range of CT071 in patients with relapsed/refractory multiple myeloma or primary plasma cell leukemia, so as to determine the possible recommended therapeutic dose (RD).

Conditions

• Multiple Myeloma
• Primary Plasma Cell Leukemia

Interventions

Type	Name	Description
DRUG	Experimental: CAR-T cells Infusion	Biological: chimeric antigen receptor T cells

Timeline

• Start date: 2023-04-28
• Primary completion: 2025-07-01
• Completion: 2025-07-01
• First posted: 2023-05-01
• Last updated: 2025-01-07

Locations

1 site across 1 country: China